KRMD

KORU Medical Systems, Inc. KRMD

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,102 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$12.05M

Quarter to Jun 30

Net income

$252.4K

Quarter to Jun 30

Free cash flow

$108.2K

Quarter to Jun 30

Operating margin

5.2%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$86.39M total
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KRMD

Earnings Per Share

13fpro.ai/company/KRMD

Loading ratio trend…

KRMD key financials by period

Reported revenue, net income and operating margin by fiscal year, from KORU Medical Systems, Inc.'s annual filings on SEC EDGAR.

KORU Medical Systems, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$41.1M$-2.6M-7.2%
FY 2024$33.6M$-6.1M-19.2%
FY 2023$28.5M$-13.7M-36.0%
FY 2022$27.9M$-8.7M-38.6%
FY 2021$23.5M$-4.6M-29.9%
FY 2020$24.2M$-1.2M-5.2%
Source: KRMD filings on SEC EDGAR →

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

KRMD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About KORU Medical Systems, Inc. (KRMD): stock profile, AI score and financials

KORU Medical Systems, Inc. (KRMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRMD at 40.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,102 of 2,925 stocks — the bottom half of the AI-ranked universe. KRMD scores in the top quartile across revenue growth (81.6). Areas of concern include revenue scale (8.5) and institutional flow (19.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), KORU Medical Systems, Inc. reports quarterly revenue of $12.0M, net income of $252.4K, an operating margin of 5.2%. Top institutional holders of KRMD by reported 13-F value include First Light Asset Management, Topline Capital Management, BlackRock, based on the most recent SEC filings. KRMD trades on the Nasdaq exchange and files with the SEC under CIK 704440. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KORU Medical Systems, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 704440 →